Elanco Animal Health (NYSE:ELAN) Issues Quarterly Earnings Results

Elanco Animal Health (NYSE:ELAN) issued its earnings results on Wednesday. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07, FiscalAI reports. The firm had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.31 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The company’s revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.26 earnings per share. Elanco Animal Health updated its Q3 2026 guidance to 0.190-0.220 EPS and its FY 2026 guidance to 1.100-1.160 EPS.

Here are the key takeaways from Elanco Animal Health’s conference call:

• Elanco reported 8% organic constant-currency revenue growth in Q2, with U.S. pet health and U.S. farm animal each up 11%; adjusted EBITDA rose 21% and adjusted EPS increased 31% year over year.
• Strong demand for Zenrelia and Credelio Quattro drove innovation revenue to $340 million in the quarter, prompting the company to raise its 2026 innovation revenue target to approximately $1.25 billion.
• Elanco raised full-year guidance to 6%-7% organic constant-currency revenue growth, $1.01-$1.035 billion of adjusted EBITDA, and $1.10-$1.16 of adjusted EPS; it also lowered its expected year-end net leverage ratio to approximately three times.
• Zenrelia treated more than 2.5 million dogs, reached 47 countries, and achieved first-line use in more than 40% of users, while Quattro expanded to over half of U.S. veterinary clinics; Befrena demand is reportedly exceeding expectations, though supply is expected to remain constrained until early 2027.
• Elanco plans to increase operating expenses by investing in direct-to-consumer marketing and product launches, with Q3 expenses expected to rise about 11% in constant currency; management also cited ongoing inflation and a seasonally more second-half-weighted margin profile.

Elanco Animal Health Stock Down 7.6%

ELAN stock traded down $1.99 during trading hours on Thursday, reaching $24.23. 17,094,858 shares of the stock were exchanged, compared to its average volume of 5,459,320. The firm’s 50-day moving average is $24.73 and its 200-day moving average is $24.10. The company has a market cap of $12.10 billion, a price-to-earnings ratio of -48.46, a PEG ratio of 1.67 and a beta of 1.67. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.16 and a quick ratio of 1.12. Elanco Animal Health has a 12 month low of $15.50 and a 12 month high of $27.98.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, insider Rajeev A. Modi acquired 4,911 shares of the stock in a transaction dated Friday, May 15th. The shares were bought at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the acquisition, the insider directly owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jeffrey N. Simmons bought 4,971 shares of Elanco Animal Health stock in a transaction that occurred on Friday, May 15th. The shares were acquired at an average price of $20.09 per share, with a total value of $99,867.39. Following the acquisition, the chief executive officer directly owned 171,971 shares of the company’s stock, valued at $3,454,897.39. The trade was a 2.98% increase in their position. The SEC filing for this purchase provides additional information. Insiders own 1.14% of the company’s stock.

Hedge Funds Weigh In On Elanco Animal Health

Large investors have recently modified their holdings of the business. Compound Planning Inc. increased its position in shares of Elanco Animal Health by 29.7% in the fourth quarter. Compound Planning Inc. now owns 21,312 shares of the company’s stock valued at $482,000 after acquiring an additional 4,876 shares during the last quarter. Invesco Ltd. boosted its position in Elanco Animal Health by 336.0% during the fourth quarter. Invesco Ltd. now owns 4,789,037 shares of the company’s stock valued at $108,376,000 after purchasing an additional 3,690,735 shares during the last quarter. Corient Private Wealth LLC grew its stake in Elanco Animal Health by 122.3% in the fourth quarter. Corient Private Wealth LLC now owns 165,381 shares of the company’s stock valued at $3,743,000 after purchasing an additional 90,993 shares in the last quarter. Mercer Global Advisors Inc. ADV increased its position in shares of Elanco Animal Health by 29.0% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 78,610 shares of the company’s stock worth $1,779,000 after purchasing an additional 17,657 shares during the last quarter. Finally, State of Tennessee Department of Treasury raised its stake in shares of Elanco Animal Health by 8.1% during the 4th quarter. State of Tennessee Department of Treasury now owns 146,658 shares of the company’s stock worth $3,532,000 after purchasing an additional 11,012 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. UBS Group lifted their price objective on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday. KeyCorp upped their target price on shares of Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday. TD Cowen lifted their price target on shares of Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. Morgan Stanley boosted their price target on shares of Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a report on Wednesday, July 22nd. Finally, Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and an average price target of $29.09.

Key Stories Impacting Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Q2 earnings and revenue exceeded expectations. Elanco reported adjusted EPS of $0.34, ahead of the $0.27 consensus, while revenue rose 10% year over year to $1.368 billion, surpassing the $1.31 billion estimate. Adjusted EBITDA was $288 million, with an adjusted EBITDA margin of 21.2%. Elanco Animal Health Reports Second Quarter 2026 Results
• Positive Sentiment: Management raised its 2026 outlook. Elanco lifted adjusted EPS guidance to $1.10-$1.16 from a prior level implied by consensus of approximately $1.07, raised revenue guidance to $5.09-$5.14 billion, and increased its adjusted EBITDA outlook to $1.01-$1.035 billion. The company also raised its innovation revenue target to $1.25 billion and expects year-end net leverage of approximately 3.0 times EBITDA. Elanco Lifts Outlook as 2Q Profit, Revenue Rise
• Positive Sentiment: Analyst sentiment improved. UBS raised its price target from $31 to $33 and assigned a “buy” rating, while KeyCorp increased its target from $29 to $30 and maintained an “overweight” rating. These targets imply substantial potential upside from recent trading levels.
• Neutral Sentiment: Zenrelia and innovation products are becoming increasingly important. Reports characterized Zenrelia as reaching blockbuster status, supporting Elanco’s growth strategy; investors will likely monitor whether the product can sustain its contribution and help deliver the raised innovation target. Elanco posts Q2 beat as Zenrelia hits blockbuster status
• Negative Sentiment: Balance-sheet and reported-profit risks remain. Elanco’s net leverage ratio was 3.1 times adjusted EBITDA, and reported net income was only $54 million, with a negative net margin. The company’s third-quarter adjusted EPS outlook of $0.19-$0.22 is broadly in line with expectations rather than an upside surprise.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.